Freij 1979b (Screened).

Methods	Quasi‐RCT Length of follow‐up: 34 days
Participants	Infected children identified by screening Number analysed for primary outcome: 44 Age range: 1 to 5 years Inclusion criteria: 92 children 1 to 5 years from a community morbidity trial Exclusion criteria: none stated
Interventions	Single dose vs placebo Piperazine: 3 g/day for 2 days Placebo: for 2 days
Outcomes	MUAC Morbidity Not included in review: weight in % of Harvard standard; authors had intended to measure bicep and tricep skinfolds, but staff were unable to take these measurements
Notes	Location: Ethiopia Burden: high Freij 1979a (Screened) and Freij 1979b (Screened) were reported in the same article. Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research Council.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Quasi‐RCT: children matched into pairs of equal age and nutritional status.
Allocation concealment (selection bias)	Unclear risk	No details reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Described as double‐blind, no further details reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	100% (44/44) of enrolled participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 100% (44/44).
Selective reporting (reporting bias)	Low risk	Trial authors had intended to measure bicep and tricep skinfolds, but staff were unable to take these measurements.
Other bias	Low risk	No obvious other source of bias.